Werewolf Therapeutics, Inc. HOWL 深 沪
交易中 02-05 10:11:13 美东时间
0.626
-0.016
-2.45%
华盛通- 最 高0.6359
- 今 开0.6285
- 成交量 6724股
- 最 低 0.61
- 昨 收 0.6417
- 总市值 2862.64万
- 52周最高 2.38
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 0.5301
- 委 比 -99.60%
- 总股本 4572.90万
- 历史最高 23.99
- 量 比 0.28
- 振 幅 4.04%
- 历史最低 0.5301
- 每 手 1
- 风险率 0.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
2025-12-22 15:05
HC Wainwright & Co. Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $4
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and lowers the price target from $10 to $4.
2025-12-19 20:44
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Athira Pharma (NASDAQ:ATHA) stock rose 70.0% to $7.03 during Thursday'...
2025-12-19 01:06
Werewolf Therapeutics Announces Pipeline and Business Updates
Werewolf Therapeutics announced data updates for its INDUKINE programs, WTX-124 and WTX-330, showing promising results in advanced cancers, including melanoma and non-small cell lung cancer. WTX-124 achieved a 30% overall response rate as a monotherapy in post-ICI melanoma patients, while WTX-330 demonstrated favorable tolerability and antitumor activity. The company plans to provide additional data updates in early 2026 and is advancing its INDU...
2025-12-18 13:00
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
2025-11-19 11:01
B of A Securities Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $7
B of A Securities analyst Jason Zemansky maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and lowers the price target from $8 to $7.
2025-11-19 01:59
Werewolf Therapeutics reports Q3 results
Werewolf Therapeutics press release (HOWL): Q3 Net loss of $16.4M vs. $16.7M previous year. As of September 30, 2025, cash and cash equivalents were $65.7 million. More on Werewolf Therapeutics Seeki...
2025-11-05 01:21
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
- Werewolf Therapeutics provided updates on their clinical trials for WTX-124 and WTX-330, with interim data and FDA meetings expected in Q4 2025. They also reported progress on WTX-1011, an INDUCER T-cell engager targeting STEAP1. Financially, the company had $65.7 million in cash as of September 2025, with Q3 2025 R&D expenses at $11.6 million, and a net loss of $16.4 million.
2025-11-04 12:00
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
Werewolf Therapeutics has received Fast Track Designation from the FDA for WTX-124, a conditionally activated IL-2 INDUKINE therapy, for the treatment of locally advanced or metastatic cutaneous melanoma following standard immunotherapy. This designation aims to expedite the development of drugs addressing serious unmet medical needs. WTX-124 is being evaluated in a Phase 1/1b trial targeting various solid tumors, aiming to stimulate anti-tumor i...
2025-10-08 12:00
Werewolf Therapeutics Faces Nasdaq Compliance Challenge
The latest announcement is out from Werewolf Therapeutics ( ($HOWL) ). Werewolf...
2025-10-07 05:00
